LEADS BIOLABS-B(09887): The first patient in the phase IB/II trial of LBL-024 for platinum-resistant ovarian cancer.
Weilitzibao-B (09887) announced that the first patient in the phase Ib/II clinical study evaluating the use of Opdivo (PD-L1/4-1BB bispecific antibody LBL-024) for the treatment of platinum-resistant ovarian cancer has successfully received treatment.
LEADS BIOLABS-B(09887) announced that the first patient in the phase Ib/II clinical study evaluating the use of the PD-L1/4-1BB bispecific antibody (LBL-024) for the treatment of platinum-resistant ovarian cancer has successfully received treatment.
This open-label, multicenter phase Ib/II clinical study is led by Professor Wu Lingying from the Cancer Hospital of the Chinese Academy of Medical Sciences, and is being conducted simultaneously in multiple hospitals across the country. The trial aims to evaluate the efficacy and safety of the combination of the PD-L1/4-1BB bispecific antibody with paclitaxel in the treatment of patients with platinum-resistant ovarian cancer.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
